Xience V stent continues to demonstrate superior efficacy over the Taxus stent up to 2 years in the SPIRIT III trial
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
May 20, 2008 By Vijayalakshmi Kunadian MBBS MD MRCP [1]
EUROPCR 08, Barcelona, Spain: Dr Gregg Stone presented the 2 years results of the SPIRIT III trial which demonstrated significant reduction in target vessel failure and major adverse cardiac events with Xience V stent vs. Taxus stent.
SPIRIT III trial is a prospective, randomized trial comparing an everolimus-eluting stent (Xience V) and a paclitaxel-eluting stent (Taxus) in patients with coronary artery disease. This study at one year demonstrated significant reduction in angiographic late-loss at 8 months, non-inferior 1-year rates of target vessel failure (TVF), reduced 1-year rates of major adverse cardiac events (MACE) and non-significant differences in the rates of protocol-defined and ARC stent thrombosis.
A total of 1002 patients from 65 US sites were enrolled in the trial and were randomized (2:1) to receive either Xience V or Taxus drug eluting stents. There were more patients with unstable angina in the Taxus group (p=0.02). Patients were treated with aspirin ≥80mg QD for 5 years and clopidogrel 75mg QD for ≥6 months. 2 year follow-up was available in 94.9% of patients. At 2 years, the primary endpoint of target vessel failure (TVF) occurred in 15.4% and 10.7% of cases in the Taxus and Xience V groups, [HR 0.68, 95%CI 0.48-0.98, p=0.04] respectively. Major adverse cardiac events occurred more frequently in the Taxus group rather than the Xience V group (12.8% vs. 7.3%, HR 0.55, 95% CI 0.36-0.83, p=0.004).
The 2 year binomial TVF and MACE favored Xience V compared with Taxus [RR 0.69, 95% CI 0.49-0.96, p=0.038 and RR 0.56, 95% CI 0.38-0.82, p=0.005]. There was a trend towards reduction in ischemia driven target lesion revascularization (TLR) with Xience V (4.3% vs. 6.9%, p=0.07). However, there was no difference in the occurrence of all cause death and cardiac death between the two groups (p=0.59 and p=0.79 respectively). There was a trend towards reduction in myocardial infarction with Xience V (3.2% vs. 5.6%, p=0.07). There was significant reduction in the combined all-cause death and myocardial infarction with Xience V (HR 0.60, 95% CI 0.35-1.01, p=0.052). At two years there was no significant difference in the incidence of stent thrombosis between the two groups (Xience V 0.9% vs. Taxus 1.6%, p=0.37). There was a trend towards reduction in stent thrombosis after discontinuation of clopidogrel at 6 months with Xience V (0.4% vs. 2.6%, p=0.10).
The SPIRIT III trial 2 year results demonstrate that the Xience V stent is associated with 32% and 45% reductions in the occurrence of TVF and MACE due to fewer peri-procedural and late myocardial infarctions and fewer TLR procedures through 2 years. Subsequent reduction in stent thrombosis after clopidogrel discontinuation requires further study.
Source
- EUROPCR Scientific Sessions, Barcelona 2008. Presented by Dr Gregg Stone.
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
